STOCK TITAN

InflaRx N.V. - IFRX STOCK NEWS

Welcome to our dedicated page for InflaRx N.V. news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on InflaRx N.V. stock.

InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing inhibitors using C5a technology, primarily in Germany and the United States. The company focuses on targeting the complement activation factor known as C5a, an inflammatory mediator linked to various autoimmune and inflammatory diseases.

InflaRx's lead product candidate is vilobelimab (formerly known as IFX-1), a first-in-class, intravenously delivered anti-C5a monoclonal antibody. Vilobelimab has completed Phase IIb clinical trials for treating hidradenitis suppurativa, a rare and chronic inflammatory skin disease, as well as for ANCA-associated vasculitis, a life-threatening autoimmune condition, and pyoderma gangrenosum, a chronic inflammatory skin disorder. Additionally, the company is exploring vilobelimab’s potential in treating oncological diseases.

InflaRx is also developing IFX-2, another anti-inflammatory and autoimmune disease treatment currently in pre-clinical development. The company’s proprietary C5a/C5aR technology enables the creation of potent and specific inhibitors, positioning InflaRx as a pioneer in this niche therapeutic area.

The company has established a co-development agreement with Beijing Defe, enhancing its research and development capacity. InflaRx's innovative therapies aim to significantly improve patient outcomes in diseases with substantial unmet medical needs.

Rhea-AI Summary

InflaRx announced that its drug GOHIBIC (vilobelimab) has been selected by BARDA for a Phase 2 clinical trial aimed at treating acute respiratory distress syndrome (ARDS). The trial will be conducted at around 60 U.S. sites, enrolling 600 adults with ARDS from various causes. Vilobelimab will be one of three drugs tested, with each drug's safety and efficacy evaluated separately against a placebo. Key endpoints include all-cause mortality at Day 28, hospitalization duration, ICU days, and other efficacy measures. The results will inform Phase 3 trial designs and identify patient subpopulations likely to benefit from these treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.44%
Tags
-
Rhea-AI Summary

InflaRx hosted a virtual R&D event showcasing their oral small molecule C5aR inhibitor, INF904. The event detailed its potential in treating Chronic Spontaneous Urticaria (CSU) and Hidradenitis Suppurativa (HS), both representing multi-billion-dollar markets. INF904's Phase 2a clinical trial for CSU and HS will start by late 2024, with results expected by summer 2025. The trial aims to evaluate safety, pharmacokinetics, and clinical benefits. InflaRx expects their strong financial position to fund operations into 2026, supporting further clinical advancements. The company sees INF904 as a pipeline-in-a-product, potentially addressing broader therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX) presented new data at the ATS 2024 International Conference showing significant improvements in mortality rates for critically ill COVID-19 patients treated with vilobelimab in combination with tocilizumab or baricitinib. The analysis, derived from the PANAMO Phase III trial, demonstrates an 84.6% relative reduction in 28-day all-cause mortality and a 66.7% relative reduction in 60-day all-cause mortality compared to placebo. Safety assessments revealed no major concerns related to the combination therapy. This data further supports the FDA's emergency use authorization for vilobelimab in critically ill COVID-19 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
clinical trial covid-19
Rhea-AI Summary

InflaRx N.V. reported financial results for Q1 2024 and provided updates on INF904 and Phase III vilobelimab trials. They highlighted plans to initiate Phase IIa in CSU and HS by 2024 end, with data availability in 2025. The vilobelimab trial for PG is ongoing, with an interim analysis in 2025. Cash reserves of €85.8 million expected to fund operations into 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX) will report its first quarter 2024 financial and operating results on May 8, 2024. They will host a virtual R&D event on June 5, 2024, focusing on the development of their new oral small molecule C5aR inhibitor, INF904, and its potential in treating chronic spontaneous urticaria and hidradenitis suppurativa. Key opinion leaders will provide insights into the commercial opportunity and therapeutic potential of INF904.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences earnings
-
Rhea-AI Summary
InflaRx, a biotechnology company focusing on anti-inflammatory therapeutics targeting the complement system, will take part in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event in NYC. They will discuss new dermatology treatments on May 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
InflaRx focuses on immuno-dermatology with vilobelimab and INF904, targeting chronic spontaneous urticaria and hidradenitis suppurativa. Partnership options for INF904 are being considered. Cash reserves expected to fund operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.88%
Tags
-
Rhea-AI Summary
InflaRx N.V. announced a conference call to discuss the development plans for INF904, an orally available C5aR inhibitor. The company will also release its financial results for Q4 and full year 2023 on March 21, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.67%
Tags
-
Rhea-AI Summary
InflaRx N.V. appoints Jan Medina as Vice President and Head of Investor Relations, bringing extensive experience in the life sciences sector and capital markets. The move aims to enhance investor relations and strengthen relationships with the investor community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
management
Rhea-AI Summary
InflaRx Pharmaceuticals Inc. has launched The InflaRx Commitment Program to cover the costs of GOHIBIC (vilobelimab) for patients who do not survive after being treated in line with its Emergency Use Authorization (EUA) for COVID-19. The program aims to encourage medical facilities to stock GOHIBIC and provide access to this potentially life-saving therapy. The FDA-authorized drug has shown improved survival rates in a multicenter Phase III trial, with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none

FAQ

What is the current stock price of InflaRx N.V. (IFRX)?

The current stock price of InflaRx N.V. (IFRX) is $2.24 as of December 20, 2024.

What is the market cap of InflaRx N.V. (IFRX)?

The market cap of InflaRx N.V. (IFRX) is approximately 127.8M.

What is InflaRx N.V.'s primary focus?

InflaRx N.V. focuses on discovering and developing inhibitors using C5a technology to treat autoimmune and inflammatory diseases.

What is vilobelimab?

Vilobelimab, formerly known as IFX-1, is InflaRx's lead product candidate, an anti-C5a monoclonal antibody designed to treat various inflammatory conditions.

Which diseases is vilobelimab being developed to treat?

Vilobelimab is being developed to treat hidradenitis suppurativa, ANCA-associated vasculitis, pyoderma gangrenosum, and oncological diseases.

What is the status of IFX-2?

IFX-2 is currently in the pre-clinical development stage and is aimed at treating chronic inflammation and autoimmune diseases.

Where does InflaRx operate?

InflaRx operates primarily in Germany and the United States.

What is C5a?

C5a is a complement activation factor and inflammatory mediator involved in a variety of autoimmune and inflammatory diseases.

Does InflaRx have any partnerships?

Yes, InflaRx has a co-development agreement with Beijing Defe to enhance its research and development efforts.

What technology does InflaRx use for its products?

InflaRx uses proprietary anti-C5a/C5aR technology to develop potent and specific inhibitors for inflammatory diseases.

What are the potential benefits of InflaRx's treatments?

InflaRx's treatments aim to provide significant improvements in patient outcomes for diseases with high unmet medical needs.

How does InflaRx's lead product candidate work?

Vilobelimab works by selectively binding to free C5a, inhibiting its role as an inflammatory mediator, thereby reducing inflammation and disease progression.

InflaRx N.V.

Nasdaq:IFRX

IFRX Rankings

IFRX Stock Data

127.78M
54.56M
7.34%
22.52%
0.41%
Biotechnology
Healthcare
Link
United States of America
Jena